PMID: 164680Jan 1, 1975Paper

The effect of triazolam on the sleep of insomniacs

G W VogelK Sexton


The effects of three oral doses of bedtime triazolam (0.25 mg, 0.5 mg, and 1.0 mg) a new benzodiazepine, on the laboratory sleep of insomniacs were studied in a double blind design which used the following 14 consecutive night schedule: 1-4 placebo; 5-11 drug; 12-14 placebo. Effects on sleep were measured objectively by conventional EEG/EOG/EMG sleep recordings and subjectively by questionnaires administered each morning. Side or toxic effects were assessed by screening physicals and questionnaires administered each morning and each evening and by a comparison of the prestudy vs. end-study physical exams and clinical lab tests. At the 0.5 mg dose triazolam significantly reduced several objective and subjective measures of insomnia. It had lesser effects at the 0.25 mg dose and equal or greater effects at 1.0 mg dose. There were no remarkable side or toxic effects at any dose.


Sep 1, 1970·Archives of General Psychiatry·A KalesJ D Kales
May 8, 1954·Nature·R COLES, F R UNDERWOOD
Nov 6, 1965·British Medical Journal·I Oswald, R G Priest


May 1, 1978·Journal of Clinical Pharmacology·M Leibowitz, A Sunshine
Jul 1, 1979·Journal of Clinical Pharmacology·A KalesE O Bixler
Jun 1, 1990·Journal of Clinical Pharmacology·M MamelakV Price
Jan 1, 1980·Psychopharmacology·C OguraW M Wardell
Jan 1, 1982·Psychopharmacology·C L Spinweber, L C Johnson
Jan 1, 1983·European Journal of Clinical Pharmacology·A Vela-BuenoA Kales
Jul 1, 1996·Psychopharmacology·L Parrino, M G Terzano
Jul 1, 1981·Electroencephalography and Clinical Neurophysiology·L C Johnson, C L Spinweber
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·R R GriffithsJ V Brady
Feb 1, 1980·British Journal of Clinical Pharmacology·A N Nicholson, B M Stone
Mar 1, 1980·British Journal of Clinical Pharmacology·A N Nicholson
Mar 1, 1983·Acta Psychiatrica Scandinavica·P A Ellingsen
Jul 1, 1987·Journal of Clinical Pharmacology·A KalesR L Manfredi
Mar 1, 1985·Journal of Clinical Pharmacology·E O BixlerC R Soldatos
Jul 1, 1982·Journal of Clinical Pharmacology·T A RoehrsT Roth
Nov 1, 1982·Journal of Clinical Pharmacology·A KalesJ D Kales
Sep 25, 2003·Sleep Medicine Reviews·Shawn D Youngstedt
Jan 1, 1990·Journal of Psychoactive Drugs·V L Martin
Jan 1, 1978·The Journal of International Medical Research·A J Bowen
Feb 1, 1991·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·E Teboul, G Chouinard
Jan 1, 1978·The Journal of International Medical Research·K K Okawa, G S Allens
Jan 1, 1977·The Journal of International Medical Research·R I WangE Hieb
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·C R SoldatosC N Stefanis
Sep 1, 1990·Hospital Practice·A Kales
Jan 1, 1980·The Journal of International Medical Research·P PiccioneT Roth
Feb 1, 1978·Journal of Clinical Pharmacology·E O BixlerJ D Kales
Jan 1, 1981·British Journal of Clinical Pharmacology·A N Nicholson
Jan 1, 1976·The Journal of International Medical Research·L F FabreR T Harris
Jan 1, 1980·The Journal of International Medical Research·V PegramP Linton
Jan 1, 1983·British Journal of Clinical Pharmacology·I GathE Bental
May 1, 1983·Pharmacotherapy·T RothF J Zorick
Jan 1, 1981·British Journal of Clinical Pharmacology·R P Purpura
Jul 1, 1983·Drug Intelligence & Clinical Pharmacy·P D Kroboth, R P Juhl

Related Concepts

Clinical Trials
Surface Electromyography
Transient Insomnia
Sleep, Slow-Wave
Sleep Stages

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Archaeal RNA Polymerase

Archaeal RNA polymerases are most similar to eukaryotic RNA polymerase II but require the support of only two archaeal general transcription factors, TBP (TATA-box binding protein) and TFB (archaeal homologue of the eukaryotic general transcription factor TFIIB) to initiate basal transcription. Here is the latest research on archaeal RNA polymerases.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.